Apple has successfully navigated a significant legal challenge regarding the blood oxygen monitoring feature of its Apple Watch. The International Trade Commission (ITC) has concluded that Apple’s redesigned version of the technology does not infringe on Masimo's patents, allowing the company to resume sales of the affected models in the United States.
In previous rulings, Apple had temporarily disabled the original feature to comply with a ban while developing a new version that processes data primarily through the iPhone. Masimo contested this redesign, claiming it still violated existing exclusion orders. However, the ITC Administrative Law Judge found in favor of Apple, stating that the new feature did not infringe upon Masimo's intellectual property.
On the heels of this ruling, the ITC declined to review the findings, effectively terminating the case and denying Masimo's request to reinstate the import ban on the original feature. This decision marks a pivotal moment in the ongoing dispute between the two companies.